<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Syndromic immunodeficiencies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Syndromic immunodeficiencies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Syndromic immunodeficiencies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey E Ming, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A number of conditions featuring immunodeficiency may also present with clinical problems that are not directly due to the immunologic deficit  (<a class="graphic graphic_table graphicRef139940" href="/z/d/graphic/139940.html" rel="external">table 1</a>) [<a href="#rid1">1-4</a>]. These inborn errors of immunity, termed "syndromic immunodeficiencies," are in contrast to other primary immunodeficiencies, in which infection is the primary manifestation and the immune problem is well characterized [<a href="#rid5">5</a>]. A large variety of manifestations have been described in the different syndromic immunodeficiencies, and a number of organ systems may be involved. Some of these conditions feature metabolic derangements or chromosomal anomalies.</p><p>In this topic review, we focus on the more common syndromic immunodeficiencies in which immune defects are noted. A number of other syndromic immunodeficiencies are listed in the table  (<a class="graphic graphic_table graphicRef139940" href="/z/d/graphic/139940.html" rel="external">table 1</a>). More complete delineation of syndromic immunodeficiencies, including rare conditions and those in which immune defects are only occasionally present, are available [<a href="#rid1">1,2</a>]. Some of these disorders are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3957.html" rel="external">"Nijmegen breakage syndrome"</a>.)</p><p class="headingAnchor" id="H1768041973"><span class="h1">IMPORTANCE OF RECOGNIZING SYNDROMIC FEATURES</span><span class="headingEndMark"> — </span>Recognition of a syndromic immunodeficiency is important in several respects [<a href="#rid6">6</a>]. For a patient with nonimmune-related anomalies who presents to the immunologist, it is critical to ascertain if the constellation of malformations is diagnostic for a specific syndrome. This may aid in giving an accurate prognosis for the immune defect. In addition, the diagnosis may alert the clinician to monitor for abnormalities in other organ systems. The prognosis for cognitive or motor development may also be impacted. Alternatively, if a child with one of these syndromes presents initially with nonimmune medical problems, then it is important to establish if an immune defect is present so that appropriate intervention can be undertaken. In addition, being able to establish the correct diagnosis may also have implications for the recurrence risk of future pregnancies of the patient or the patient's family and relatives.</p><p class="headingAnchor" id="H2"><span class="h1">CARTILAGE-HAIR HYPOPLASIA</span><span class="headingEndMark"> — </span>Cartilage-hair hypoplasia (CHH) is a rare, autosomal recessive form of short-limb dwarfism (metaphyseal chondrodysplasia). Associated features may include fine, sparse hair; cellular and humoral immunodeficiencies; Hirschsprung disease; hematologic and skin malignancies; autoimmune disease; and bronchiectasis. CHH is caused by defects in the ribonuclease mitochondrial RNA-processing (<em>RMRP</em>) gene. This disorder is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3916.html" rel="external">"Cartilage-hair hypoplasia"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ICF SYNDROME</span><span class="headingEndMark"> — </span>The ICF syndrome is an autosomal recessive condition comprised of <strong>I</strong>mmunodeficiency, <strong>C</strong>entromeric instability, and <strong>F</strong>acial anomalies [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Chromosomal methylation is defective in affected patients [<a href="#rid8">8</a>]. Mutations in the gene DNA methyltransferase 3 beta (<em>DNMT3B</em>), which encodes a DNA methyltransferase, are causative in approximately half of individuals with this syndrome [<a href="#rid9">9,10</a>]. However, other patients diagnosed with ICF do not have identified <em>DNMT3B</em> mutations [<a href="#rid11">11,12</a>]. Mutations in the zinc finger and BTB domain-containing 24 (<em>ZBTB24</em>) gene, which encodes a transcriptional repressor involved in DNA methylation, were identified in some of these patients [<a href="#rid13">13</a>]. There are not any apparent clinical differences between those patients with a <em>DNMT3B</em> mutation and those with a <em>ZBTB24</em> mutation.</p><p class="headingAnchor" id="H5"><span class="h2">Clinical manifestations and laboratory abnormalities</span><span class="headingEndMark"> — </span>Intellectual disability frequently occurs. Characteristic facial features include ocular hypertelorism, flat nasal bridge, epicanthal folds, and low-set ears.</p><p>Immunodeficiency is manifest by the development of sinopulmonary, gastrointestinal, and cutaneous infections. The immune defect may affect both immunoglobulin levels and T cell number and function. Generally, at least two immunoglobulin classes are affected in each patient, and agammaglobulinemia can occur [<a href="#rid14">14,15</a>]. T cell number and response to mitogen may be decreased [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The centromeric instability most frequently involves chromosomes 1 and 16, often 9, and rarely 2 and 10 [<a href="#rid14">14,17</a>]. Deletions, breaks, interchanges between homologous and nonhomologous chromosomes, and multibranched configurations involving pericentric heterochromatin have been described. The ICF syndrome differs from other chromosome instability syndromes in that no hypersensitivity to clastogenic agents has been demonstrated, so the condition should not be considered a chromosome breakage syndrome.</p><p>The diagnosis should be considered in individuals with immunodeficiency and the characteristic facial appearance. Most patients have intellectual disability, although some patients have normal cognitive development [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment is supportive and is directed to the specific clinical and immunologic problems present in the individual. Allogeneic hematopoietic cell transplantation (HCT) in patients with severe disease corrects the immunodeficiency and improves growth [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p>Early diagnosis and intervention can improve outcome [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H8"><span class="h1">GRISCELLI SYNDROME</span><span class="headingEndMark"> — </span>The Griscelli syndrome is an autosomal recessive syndrome that features hypopigmentation and may include immunodeficiency and/or neurologic deficits, depending upon the specific genetic defect.</p><p class="headingAnchor" id="H9"><span class="h2">Clinical manifestations and laboratory abnormalities</span><span class="headingEndMark"> — </span>This condition is characterized by partial albinism, neutropenia and thrombocytopenia, and hemophagocytic lymphohistiocytosis [<a href="#rid21">21-24</a>]. Neurologic involvement may be progressive, possibly due to cerebral lymphohistiocytic infiltration [<a href="#rid25">25,26</a>].</p><p>Melanosomes accumulate in melanocytes, causing clumps of pigment in hair shafts. The absence of giant granules and the histologic characteristics of the hypopigmentation differentiate this condition from Chediak-Higashi syndrome. (See  <a class="medical medical_review" href="/z/d/html/3926.html" rel="external">"Chediak-Higashi syndrome"</a>.)</p><p>The hemophagocytosis may be associated with a viral infection [<a href="#rid27">27</a>]. Neurologic complications may be caused by lymphohistiocytosis of the central nervous system.</p><p>Patients are susceptible to fungal, viral, and bacterial infections. The immune abnormalities may affect both the cellular and the humoral immune response, with neutropenia also being noted [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Griscelli syndrome should be considered in infants with silvery-gray hair, hepatosplenomegaly, and immunodeficiency. Microscopic examination of the hair shaft can be used to confirm the diagnosis.</p><p class="headingAnchor" id="H11"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Several mutations have been found in affected patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Mutations in myosin VA (<em>MYO5A</em>), which encodes an unconventional myosin, were detected in affected patients with neurologic symptoms who <strong>lacked</strong> the hemophagocytic syndrome and also <strong>lacked</strong> immunologic deficits [<a href="#rid28">28,29</a>]. This is referred to as type 1 Griscelli syndrome (GS1, MIM#214450).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations in RAB27A, member RAS oncogene family (<em>RAB27A</em>), which encodes a guanosine triphosphate (GTP)-binding protein of the Ras family, were identified in patients presenting primarily with the hemophagocytic syndrome and abnormal T cell and macrophage activation with variable neurologic involvement [<a href="#rid29">29</a>]. This is termed type 2 Griscelli syndrome (GS2, MIM#607624) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 3 Griscelli syndrome (GS3, MIM#609227) is characterized by partial albinism alone, without immune or neurologic complications, and this type can be due to a mutation in <em>MYO5A</em> or in the gene that encodes for melanophilin (<em>MLPH</em>) [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Most patients with GS1 or GS2 die in childhood, usually secondary to severe neurologic sequelae or recurrent infection. Hematopoietic cell transplantation (HCT) is the only available curative therapy that has shown some success for patients with GS2 with hemophagocytic lymphohistiocytosis and immunodeficiency [<a href="#rid26">26,32-35</a>]. Patients with GS3 have a better prognosis since they lack immune and neurologic complications.</p><p class="headingAnchor" id="H13"><span class="h1">p14 DEFICIENCY</span><span class="headingEndMark"> — </span>A syndrome of severe congenital neutropenia, short stature, cutaneous hypopigmentation, coarse facial features, and recurrent respiratory infections with <em>Streptococcus pneumoniae</em> has been described in four members of a single White family [<a href="#rid36">36</a>]. Deficiency of the endosomal adaptor protein p14 (also known as MAPBPIP, encoded by the late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 [<em>LAMTOR2</em>] gene) was identified in all patients, and functional reconstitution of granule activity was achieved with p14 gene transfer [<a href="#rid36">36</a>]. Defects in cytotoxic T cell activity and abnormal B cell differentiation were also noted.</p><p class="headingAnchor" id="H14"><span class="h1">SCHIMKE IMMUNOOSSEOUS DYSPLASIA</span><span class="headingEndMark"> — </span>Schimke immunoosseous dysplasia (SIOD) is an autosomal recessive condition, which features skeletal, renal, and immune abnormalities.</p><p class="headingAnchor" id="H15"><span class="h2">Clinical manifestations and laboratory abnormalities</span><span class="headingEndMark"> — </span>The principal features of SIOD include short stature (often with prenatal growth deficiency), spondyloepiphyseal dysplasia, defective cellular immunity, and progressive renal failure [<a href="#rid37">37,38</a>].</p><p>Additional specific abnormalities may be seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperpigmented macules are frequently present, especially on the trunk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with short stature have disproportionate shortening of the trunk and lumbar lordosis. The vertebral bodies may be abnormally shaped, and epiphyseal changes are most frequently present in the proximal femur [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal opacities and other ophthalmologic abnormalities may be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients eventually develop proteinuria and nephrotic syndrome, usually due to focal segmental glomerulosclerosis. This frequently progresses to end-stage kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 50 percent have an arteriopathy with cerebral infarcts and/or ischemia. Most patients have normal cognitive development, and those with developmental delay have only a mild delay.</p><p></p><p>Patients are prone to viral, fungal, and bacterial infections, with recurrent infections being noted in approximately one-half of patients. T cell deficiency with decreased CD4+ number, absent interleukin 7 receptor alpha chain (IL7RA) expression, and impaired T cell function are often present [<a href="#rid38">38-41</a>]. Humoral defects also occur. Lymphopenia is characteristic (94 percent), can be recurrent, and is often associated with other hematologic abnormalities, including pancytopenia.</p><p class="headingAnchor" id="H16"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis should be considered in patients with short stature and immunodeficiency. Renal function should be assessed if the diagnosis is suspected. Radiographs for the characteristic bony anomalies should be performed.</p><p class="headingAnchor" id="H17"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Mutations in the gene encoding the chromatin remodeling protein, SWI/SNF2-related matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1 (SMARCAL1), have been detected in affected patients [<a href="#rid42">42</a>]. The protein participates in DNA-nucleosome restructuring that occurs during gene regulation and DNA replication and recombination. Patients with defects in this gene have reduced thymic function that correlates with clinical phenotype [<a href="#rid43">43</a>]. Other genetic loci may also be involved since almost half of affected patients do not have detectable mutations in the coding region of <em>SMARCAL1</em> [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Thyroid, renal, and immune function should be monitored on a yearly basis. T cell number, subsets, and function should be assessed. Since humoral defects can also occur, evaluation for these abnormalities should be performed.</p><p>Renal transplants have been successfully used for those who progress to end-stage kidney disease [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/z/d/html/6120.html" rel="external">"Kidney transplantation in children: General principles"</a>). Of note, transplanted kidneys generally do not show recurrence of the renal disease [<a href="#rid45">45</a>]. Hematopoietic cell transplantation (HCT) has been used to improve bone marrow function in severely affected cases, with one child showing markedly improved function at two years posttransplant [<a href="#rid46">46</a>]. However, HCT has not been successful for other patients [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H4290605047"><span class="h1">ROIFMAN SYNDROME</span><span class="headingEndMark"> — </span>Roifman syndrome is an autosomal recessive condition characterized by microcephaly, growth retardation, spondyloepiphyseal dysplasia, developmental delay, and retinal dystrophy.</p><p class="headingAnchor" id="H2943788297"><span class="h2">Clinical manifestations and laboratory abnormalities</span><span class="headingEndMark"> — </span>This condition is characterized by spondyloepiphyseal dysplasia, short stature, developmental delay, and a characteristic facial appearance [<a href="#rid48">48-50</a>]. Retinal dystrophy may also occur.</p><p>Patients may have recurrent infections with low specific antibody titers in response to infection. Reduced mitogenic response to <em>Staphylococcus aureus</em> Cowan antigen has been reported. T cell number and function are normal.</p><p class="headingAnchor" id="H1725482789"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis should be considered in patients with developmental delay, disproportionate short stature, and immunodeficiency. Radiographs for spondyloepiphyseal dysplasia should be performed.</p><p class="headingAnchor" id="H1153723872"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Compound heterozygous mutations in the RNA, U4atac small nuclear U12-dependent splicing (<em>RNU4ATAC</em>) gene have been identified in affected patients [<a href="#rid51">51</a>].<strong> </strong>The mutations of this spliceosome component result in defects of minor intron splicing.<strong> </strong>Mutations in this gene have also been detected in patients with microcephalic osteodysplastic primordial dwarfism, type I (MOPD1), which has different associated clinical features.</p><p class="headingAnchor" id="H804897437"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Development should be monitored. Screening for retinal abnormalities can be performed. Since humoral immunity abnormalities frequently occur, assessment for these defects should be performed.</p><p class="headingAnchor" id="H215400003"><span class="h1">ROIFMAN-CHITAYAT SYNDROME</span><span class="headingEndMark"> — </span>Roifman-Chitayat syndrome is an autosomal recessive condition characterized by combined immunodeficiency, developmental delay, optic nerve atrophy, and skeletal anomalies.</p><p class="headingAnchor" id="H1623266303"><span class="h2">Clinical manifestations and laboratory abnormalities</span><span class="headingEndMark"> — </span>Optic nerve atrophy, myoclonic seizures, skeletal anomalies (cone-shaped epiphyses, short metacarpals and metatarsals), and developmental delay were described in two sisters of consanguineous parents [<a href="#rid52">52</a>]. Facial features included hypoplastic supraorbital ridges, hypertelorism, a flat nasal bridge, a broad nasal root, and a square chin. Both patients had severe recurrent infections, including recurrent otitis media, and multiple episodes of bacterial and viral pneumonia (including <em>S. pneumoniae</em> septicemia). In addition, the older sister had persistent oral thrush, and the younger sister had parainfluenzae pneumonitis with bronchial lavage showing <em>Pneumocystis jiroveci</em> and <em>Klebsiella aerogenes</em>, prolonged rotavirus-associated diarrhea, and oral thrush.</p><p>Both sisters had hypogammaglobulinemia and inadequate response to immunizations, as well as decreased response to mitogens. The number and proportion of T cell subsets were normal to elevated, with reduced natural killer cell numbers and borderline low B cell numbers.</p><p class="headingAnchor" id="H1798562528"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis should be considered in patients with developmental delay, skeletal anomalies, seizures, optic nerve atrophy, and combined immunodeficiency. Radiographs for the skeletal anomalies should be performed if other findings suggest the diagnosis.</p><p class="headingAnchor" id="H2857826297"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Homozygous loss-of-function mutations resulting in protein truncation were detected in both phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (<em>PIK3CD</em>; encoding phosphatidylinositol 3 [PI3]-kinase p110 delta) and kinetochore-localized astrin (SPAG5) binding protein (<em>KNSTRN</em>; encoding small kinetochore-associated protein [SKAP]) [<a href="#rid53">53</a>]. The features present in the patients are probably due to contributions from abnormalities in both genes.</p><p class="headingAnchor" id="H507334919"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Development should be monitored. Patients should be screened for optic nerve abnormalities and assessed for immunologic defects. <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> replacement therapy may be indicated as it led to reduced frequency of infections in the older sister described above [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H19"><span class="h1">DELETION OF CHROMOSOME REGION 22Q11.2 (DiGEORGE SYNDROME)</span><span class="headingEndMark"> — </span>Deletion of the 22q11.2 chromosome region is associated with the clinical conditions DiGeorge syndrome, velocardiofacial syndrome (VCFS), and (less commonly) Opitz G/BBB (oculogenitolaryngeal) syndrome. DiGeorge syndrome and VCFS are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2926.html" rel="external">"Syndromes with craniofacial abnormalities"</a>.)</p><p>The Opitz G/BBB syndrome is characterized by ocular hypertelorism, hypospadias, and laryngoesophageal defects. Some patients diagnosed with Opitz G/BBB syndrome have deletions of 22q11, although mutations in a gene on chromosome Xp22, named midline 1 (<em>MID1</em>), have been identified in others [<a href="#rid54">54</a>]. It is likely that a relatively small proportion of patients with Opitz G/BBB have deletions of 22q11.</p><p class="headingAnchor" id="H20"><span class="h1">DELETIONS OF CHROMOSOME REGION 10p13-p14</span><span class="headingEndMark"> — </span>Deletions of the chromosome region 10p13-p14 are also associated with DiGeorge syndrome [<a href="#rid55">55,56</a>]. The deletions in these patients generally extend beyond the DiGeorge syndrome critical region to include the GATA-binding protein 3 (<em>GATA3</em>) gene [<a href="#rid57">57</a>]. This gene is also mutated in the syndrome of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome [<a href="#rid58">58</a>]. Patients with DiGeorge syndrome and 10p13-14 deletions more often have deafness than patients with underlying mutations in 22q11. (See  <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">PARTIAL DELETIONS OF CHROMOSOME 4p (WOLF-HIRSCHHORN SYNDROME)</span><span class="headingEndMark"> — </span>Deletions of chromosome 4p are associated with intellectual disability, growth deficiency, and immunodeficiencies. The critical region for the deletion is on chromosome 4p16.3. The deletion occurs de novo in approximately 87 percent of cases (approximately 80 percent involve the paternal chromosome) and, in the remainder of the cases, is due to a balanced translocation in one of the parents (most involve the maternal chromosome) [<a href="#rid59">59-61</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Clinical manifestations, laboratory abnormalities, and pathogenesis</span><span class="headingEndMark"> — </span>Affected patients often have prenatal and postnatal growth failure, intellectual disability, microcephaly, widely spaced eyes, and seizures. Hearing loss, optic coloboma, renal anomalies, structural brain anomalies, skeletal anomalies, abnormal tooth development, and congenital heart disease may also be present [<a href="#rid62">62</a>]. There is some correlation between deletion size and clinical severity [<a href="#rid63">63</a>].</p><p>Patients have frequent episodes of respiratory infections due in part to recurrent aspiration. Antibody deficiencies are also common. Immune defects include common variable immunodeficiency, immunoglobulin A (IgA) and immunoglobulin G2 (IgG2) subclass deficiency, IgA deficiency, and impaired polysaccharide responsiveness [<a href="#rid64">64</a>]. T cell immunity is normal. Immunodeficiency does not appear to correlate with deletion size.</p><p>The exact pathogenesis of Wolf-Hirschhorn syndrome (WHS) is unknown. Wolf-Hirschhorn syndrome candidate 1 (<em>WHSC1</em>) gene is deleted in all known cases of WHS. This gene encodes an H3K36me3-specific histone methyltransferase (HMTase) that plays a role in transcriptional regulation. One of the factors that <em>WHSC1</em> modulates is Nkx2-5, a central transcriptional regulator of cardiac development. The interaction of <em>WHSC1</em> with multiple different transcription factors may account for the variability in clinical phenotype [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Many of the deletions are cytogenetically visible on a standard karyotype. In some cases, molecular techniques may be required for the diagnosis if the deletion is relatively small, such as fluorescence in situ hybridization (FISH) or array-based approaches.</p><p class="headingAnchor" id="H24"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment is supportive and directed to the specific clinical indications. Feeding difficulties are often present, and, if indicated, gastrostomy tube placement may be considered [<a href="#rid66">66</a>]. Audiologic screen, ophthalmologic evaluation, and careful cardiac exam may be performed. Developmental evaluation and appropriate intervention should be undertaken. Chromosome analysis of the parents should be performed.</p><p class="headingAnchor" id="H25"><span class="h1">BLOOM SYNDROME</span><span class="headingEndMark"> — </span>Bloom syndrome, an autosomal recessive condition, is associated with short stature, a characteristic facial appearance, and increased risk of neoplasia. Bloom syndrome has been reported in a variety of ethnic groups, with an increased frequency in the Ashkenazi-Jewish population. This condition is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">NIJMEGEN BREAKAGE SYNDROME</span><span class="headingEndMark"> — </span>Nijmegen breakage syndrome, an autosomal recessive condition, is characterized by short stature and immune defects. The condition has been most frequently described in patients of Eastern European ancestry. This disorder is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3957.html" rel="external">"Nijmegen breakage syndrome"</a>.)</p><p class="headingAnchor" id="H1102765182"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H3253291"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – A number of conditions featuring immunodeficiency may also present with clinical problems that are not directly due to the immunologic deficit  (<a class="graphic graphic_table graphicRef139940" href="/z/d/graphic/139940.html" rel="external">table 1</a>). These inborn errors of immunity, termed "syndromic immunodeficiencies," are in contrast to other primary immunodeficiencies, in which infection is the primary manifestation and the immune problem is well characterized. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ICF syndrome</strong> – The immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome is an autosomal recessive condition caused by defective chromosomal methylation. Intellectual disability frequently occurs. Characteristic facial features include ocular hypertelorism, flat nasal bridge, epicanthal folds, and low-set ears. Immunodeficiency is manifest by the development of sinopulmonary, gastrointestinal, and cutaneous infections. (See <a class="local">'ICF syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Griscelli syndrome type 2</strong> – GS2 is an autosomal recessive condition characterized by partial albinism, neutropenia and thrombocytopenia, and hemophagocytic lymphohistiocytosis. Neurologic involvement may be progressive. Patients are susceptible to fungal, viral, and bacterial infections. (See <a class="local">'Griscelli syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schimke immunoosseous dysplasia</strong> – SIOD is an autosomal recessive condition with the principal features of short stature (often with prenatal growth deficiency), spondyloepiphyseal dysplasia, defective cellular immunity, and progressive renal failure. Patients are prone to viral, fungal, and bacterial infections. (See <a class="local">'Schimke immunoosseous dysplasia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Roifman syndrome</strong> – Roifman syndrome is an autosomal recessive condition characterized by microcephaly, growth retardation, spondyloepiphyseal dysplasia, developmental delay, and retinal dystrophy. (See <a class="local">'Roifman syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial deletions of chromosome 4p</strong> – Partial deletions of chromosome 4p are associated with intellectual disability, growth deficiency, and immunodeficiencies. Patients have frequent episodes of respiratory infections due in part to recurrent aspiration. Antibody deficiencies are common, but T cell immunity is normal. (See <a class="local">'Partial deletions of chromosome 4p (Wolf-Hirschhorn syndrome)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other syndromic immunodeficiencies</strong> – Syndromic immunodeficiencies that are discussed in other topic reviews include cartilage-hair hypoplasia (CHH); p14 deficiency; deletion of the 22q11.2 chromosome region that is associated with the clinical conditions DiGeorge syndrome, velocardiofacial syndrome (VCFS), and (less commonly) Opitz G/BBB syndrome; deletions of the chromosome region 10p13-p14 that are also associated with DiGeorge syndrome; Bloom syndrome; Nijmegen breakage syndrome, Wiskott-Aldrich syndrome, and ataxia-telangiectasia . (See  <a class="medical medical_review" href="/z/d/html/3916.html" rel="external">"Cartilage-hair hypoplasia"</a> and  <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2926.html" rel="external">"Syndromes with craniofacial abnormalities", section on 'Velocardiofacial (Shprintzen) syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/3959.html" rel="external">"Bloom syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3957.html" rel="external">"Nijmegen breakage syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>.)</p><p></p><p class="headingAnchor" id="H4294227008"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ming JE, Stiehm ER, Graham JM Jr. Syndromic immunodeficiencies: genetic syndromes associated with immune abnormalities. Crit Rev Clin Lab Sci 2003; 40:587.</a></li><li><a class="nounderline abstract_t">Ming JE, Stiehm ER. Genetic syndromic immunodeficiencies with antibody defects. Immunol Allergy Clin North Am 2008; 28:715.</a></li><li><a class="nounderline abstract_t">Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</a></li><li class="breakAll">Ming JE, Graham JM Jr. Genetic syndromes with evidence of immune deficiency. In: Stiehm's Immune Deficiencies, Sullivan KE, Stiehm ER (Eds), Elsevier, Philadelphia 2015. p.281.</li><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li><a class="nounderline abstract_t">Szczawinska-Poplonyk A, Begier K, Dorota A, et al. Syndromic immunodeficiencies: a pediatrician's perspective on selected diseases. Allergol Immunopathol (Madr) 2021; 49:117.</a></li><li><a class="nounderline abstract_t">Hagleitner MM, Lankester A, Maraschio P, et al. Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome). J Med Genet 2008; 45:93.</a></li><li><a class="nounderline abstract_t">Jeanpierre M, Turleau C, Aurias A, et al. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Hum Mol Genet 1993; 2:731.</a></li><li><a class="nounderline abstract_t">Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99:247.</a></li><li><a class="nounderline abstract_t">Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402:187.</a></li><li><a class="nounderline abstract_t">Kloeckener-Gruissem B, Betts DR, Zankl A, et al. A new and a reclassified ICF patient without mutations in DNMT3B and its interacting proteins SUMO-1 and UBC9. Am J Med Genet A 2005; 136:31.</a></li><li><a class="nounderline abstract_t">Jiang YL, Rigolet M, Bourc'his D, et al. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum Mutat 2005; 25:56.</a></li><li><a class="nounderline abstract_t">de Greef JC, Wang J, Balog J, et al. Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Am J Hum Genet 2011; 88:796.</a></li><li><a class="nounderline abstract_t">Maraschio P, Zuffardi O, Dalla Fior T, Tiepolo L. Immunodeficiency, centromeric heterochromatin instability of chromosomes 1, 9, and 16, and facial anomalies: the ICF syndrome. J Med Genet 1988; 25:173.</a></li><li><a class="nounderline abstract_t">Smeets DF, Moog U, Weemaes CM, et al. ICF syndrome: a new case and review of the literature. Hum Genet 1994; 94:240.</a></li><li><a class="nounderline abstract_t">Fasth A, Forestier E, Holmberg E, et al. Fragility of the centromeric region of chromosome 1 associated with combined immunodeficiency in siblings. A recessively inherited entity? Acta Paediatr Scand 1990; 79:605.</a></li><li><a class="nounderline abstract_t">Tiepolo L, Maraschio P, Gimelli G, et al. Multibranched chromosomes 1, 9, and 16 in a patient with combined IgA and IgE deficiency. Hum Genet 1979; 51:127.</a></li><li><a class="nounderline abstract_t">Shirohzu H, Kubota T, Kumazawa A, et al. Three novel DNMT3B mutations in Japanese patients with ICF syndrome. Am J Med Genet 2002; 112:31.</a></li><li><a class="nounderline abstract_t">Gennery AR, Slatter MA, Bredius RG, et al. Hematopoietic stem cell transplantation corrects the immunologic abnormalities associated with immunodeficiency-centromeric instability-facial dysmorphism syndrome. Pediatrics 2007; 120:e1341.</a></li><li><a class="nounderline abstract_t">De Ravel TJ, Deckers E, Alliet PL, et al. The ICF syndrome: new case and update. Genet Couns 2001; 12:379.</a></li><li><a class="nounderline abstract_t">Griscelli C, Durandy A, Guy-Grand D, et al. A syndrome associating partial albinism and immunodeficiency. Am J Med 1978; 65:691.</a></li><li><a class="nounderline abstract_t">Mancini AJ, Chan LS, Paller AS. Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature. J Am Acad Dermatol 1998; 38:295.</a></li><li><a class="nounderline abstract_t">Dufourcq-Lagelouse R, Pastural E, Barrat FJ, et al. Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review). Int J Mol Med 1999; 4:127.</a></li><li><a class="nounderline abstract_t">Cağdaş D, Ozgür TT, Asal GT, et al. Griscelli syndrome types 1 and 3: analysis of four new cases and long-term evaluation of previously diagnosed patients. Eur J Pediatr 2012; 171:1527.</a></li><li><a class="nounderline abstract_t">Hurvitz H, Gillis R, Klaus S, et al. A kindred with Griscelli disease: spectrum of neurological involvement. Eur J Pediatr 1993; 152:402.</a></li><li><a class="nounderline abstract_t">Klein C, Philippe N, Le Deist F, et al. Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr 1994; 125:886.</a></li><li><a class="nounderline abstract_t">Kumar M, Sackey K, Schmalstieg F, et al. Griscelli syndrome: rare neonatal syndrome of recurrent hemophagocytosis. J Pediatr Hematol Oncol 2001; 23:464.</a></li><li><a class="nounderline abstract_t">Pastural E, Barrat FJ, Dufourcq-Lagelouse R, et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet 1997; 16:289.</a></li><li><a class="nounderline abstract_t">Ménasché G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000; 25:173.</a></li><li><a class="nounderline abstract_t">Masri A, Bakri FG, Al-Hussaini M, et al. Griscelli syndrome type 2: a rare and lethal disorder. J Child Neurol 2008; 23:964.</a></li><li><a class="nounderline abstract_t">Ménasché G, Ho CH, Sanal O, et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest 2003; 112:450.</a></li><li><a class="nounderline abstract_t">Schuster F, Stachel DK, Schmid I, et al. Griscelli syndrome: report of the first peripheral blood stem cell transplant and the role of mutations in the RAB27A gene as an indication for BMT. Bone Marrow Transplant 2001; 28:409.</a></li><li><a class="nounderline abstract_t">Schneider LC, Berman RS, Shea CR, et al. Bone marrow transplantation (BMT) for the syndrome of pigmentary dilution and lymphohistiocytosis (Griscelli's syndrome). J Clin Immunol 1990; 10:146.</a></li><li><a class="nounderline abstract_t">Pachlopnik Schmid J, Moshous D, Boddaert N, et al. Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients. Blood 2009; 114:211.</a></li><li><a class="nounderline abstract_t">Al-Ahmari A, Al-Ghonaium A, Al-Mansoori M, et al. Hematopoietic SCT in children with Griscelli syndrome: a single-center experience. Bone Marrow Transplant 2010; 45:1294.</a></li><li><a class="nounderline abstract_t">Bohn G, Allroth A, Brandes G, et al. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat Med 2007; 13:38.</a></li><li><a class="nounderline abstract_t">Saraiva JM, Dinis A, Resende C, et al. Schimke immuno-osseous dysplasia: case report and review of 25 patients. J Med Genet 1999; 36:786.</a></li><li><a class="nounderline abstract_t">Boerkoel CF, O'Neill S, André JL, et al. Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literature. Eur J Pediatr 2000; 159:1.</a></li><li><a class="nounderline abstract_t">Spranger J, Hinkel GK, Stöss H, et al. Schimke immuno-osseous dysplasia: a newly recognized multisystem disease. J Pediatr 1991; 119:64.</a></li><li><a class="nounderline abstract_t">Ludman MD, Cole DE, Crocker JF, Cohen MM Jr. Schimke immuno-osseous dysplasia: case report and review. Am J Med Genet 1993; 47:793.</a></li><li><a class="nounderline abstract_t">Sanyal M, Morimoto M, Baradaran-Heravi A, et al. Lack of IL7Rα expression in T cells is a hallmark of T-cell immunodeficiency in Schimke immuno-osseous dysplasia (SIOD). Clin Immunol 2015; 161:355.</a></li><li><a class="nounderline abstract_t">Boerkoel CF, Takashima H, John J, et al. Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. Nat Genet 2002; 30:215.</a></li><li><a class="nounderline abstract_t">Lev A, Amariglio N, Levy Y, et al. Molecular assessment of thymic capacities in patients with Schimke immuno-osseous dysplasia. Clin Immunol 2009; 133:375.</a></li><li><a class="nounderline abstract_t">Clewing JM, Fryssira H, Goodman D, et al. Schimke immunoosseous dysplasia: suggestions of genetic diversity. Hum Mutat 2007; 28:273.</a></li><li><a class="nounderline abstract_t">Elizondo LI, Huang C, Northrop JL, et al. Schimke immuno-osseous dysplasia: a cell autonomous disorder? Am J Med Genet A 2006; 140:340.</a></li><li><a class="nounderline abstract_t">Petty EM, Yanik GA, Hutchinson RJ, et al. Successful bone marrow transplantation in a patient with Schimke immuno-osseous dysplasia. J Pediatr 2000; 137:882.</a></li><li><a class="nounderline abstract_t">Baradaran-Heravi A, Lange J, Asakura Y, et al. Bone marrow transplantation in Schimke immuno-osseous dysplasia. Am J Med Genet A 2013; 161A:2609.</a></li><li><a class="nounderline abstract_t">Roifman CM. Antibody deficiency, growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy: a novel syndrome. Clin Genet 1999; 55:103.</a></li><li><a class="nounderline abstract_t">de Vries PJ, McCartney DL, McCartney E, et al. The cognitive and behavioural phenotype of Roifman syndrome. J Intellect Disabil Res 2006; 50:690.</a></li><li><a class="nounderline abstract_t">Gray PE, Sillence D, Kakakios A. Is Roifman syndrome an X-linked ciliopathy with humoral immunodeficiency? Evidence from 2 new cases. Int J Immunogenet 2011; 38:501.</a></li><li><a class="nounderline abstract_t">Merico D, Roifman M, Braunschweig U, et al. Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing. Nat Commun 2015; 6:8718.</a></li><li><a class="nounderline abstract_t">Roifman CM, Chitayat D. Combined immunodeficiency, facial dysmorphism, optic nerve atrophy, skeletal anomalies and developmental delay: a new syndrome. Clin Genet 2009; 76:449.</a></li><li><a class="nounderline abstract_t">Sharfe N, Karanxha A, Dadi H, et al. Dual loss of p110δ PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features. J Allergy Clin Immunol 2018; 142:618.</a></li><li><a class="nounderline abstract_t">Quaderi NA, Schweiger S, Gaudenz K, et al. Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nat Genet 1997; 17:285.</a></li><li><a class="nounderline abstract_t">Greenberg F, Elder FF, Haffner P, et al. Cytogenetic findings in a prospective series of patients with DiGeorge anomaly. Am J Hum Genet 1988; 43:605.</a></li><li><a class="nounderline abstract_t">Daw SC, Taylor C, Kraman M, et al. A common region of 10p deleted in DiGeorge and velocardiofacial syndromes. Nat Genet 1996; 13:458.</a></li><li><a class="nounderline abstract_t">Lichtner P, König R, Hasegawa T, et al. An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13/14. J Med Genet 2000; 37:33.</a></li><li><a class="nounderline abstract_t">Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000; 406:419.</a></li><li><a class="nounderline abstract_t">Estabrooks LL, Rao KW, Driscoll DA, et al. Preliminary phenotypic map of chromosome 4p16 based on 4p deletions. Am J Med Genet 1995; 57:581.</a></li><li><a class="nounderline abstract_t">Wright TJ, Ricke DO, Denison K, et al. A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region. Hum Mol Genet 1997; 6:317.</a></li><li><a class="nounderline abstract_t">Dallapiccola B, Mandich P, Bellone E, et al. Parental origin of chromosome 4p deletion in Wolf-Hirschhorn syndrome. Am J Med Genet 1993; 47:921.</a></li><li><a class="nounderline abstract_t">Battaglia A, Filippi T, Carey JC. Update on the clinical features and natural history of Wolf-Hirschhorn (4p-) syndrome: experience with 87 patients and recommendations for routine health supervision. Am J Med Genet C Semin Med Genet 2008; 148C:246.</a></li><li><a class="nounderline abstract_t">Zollino M, Murdolo M, Marangi G, et al. On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet 2008; 148C:257.</a></li><li><a class="nounderline abstract_t">Hanley-Lopez J, Estabrooks LL, Stiehm R. Antibody deficiency in Wolf-Hirschhorn syndrome. J Pediatr 1998; 133:141.</a></li><li><a class="nounderline abstract_t">Nimura K, Ura K, Shiratori H, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009; 460:287.</a></li><li><a class="nounderline abstract_t">Battaglia A, Carey JC, Cederholm P, et al. Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases. Pediatrics 1999; 103:830.</a></li></ol></div><div id="topicVersionRevision">Topic 3951 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14708957" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Syndromic immunodeficiencies: genetic syndromes associated with immune abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940571" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genetic syndromic immunodeficiencies with antibody defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice parameter for the diagnosis and management of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Practice parameter for the diagnosis and management of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224226" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Syndromic immunodeficiencies: a pediatrician's perspective on selected diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17893117" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102570" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555141" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10647011" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15952214" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A new and a reclassified ICF patient without mutations in DNMT3B and its interacting proteins SUMO-1 and UBC9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580563" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : DNMT3B mutations and DNA methylation defect define two types of ICF syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596365" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3351904" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Immunodeficiency, centromeric heterochromatin instability of chromosomes 1, 9, and 16, and facial anomalies: the ICF syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076938" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ICF syndrome: a new case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2386052" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fragility of the centromeric region of chromosome 1 associated with combined immunodeficiency in siblings. A recessively inherited entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/511139" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multibranched chromosomes 1, 9, and 16 in a patient with combined IgA and IgE deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12239717" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Three novel DNMT3B mutations in Japanese patients with ICF syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908720" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hematopoietic stem cell transplantation corrects the immunologic abnormalities associated with immunodeficiency-centromeric instability-facial dysmorphism syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11837609" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The ICF syndrome: new case and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707528" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A syndrome associating partial albinism and immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486701" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10402477" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711375" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Griscelli syndrome types 1 and 3: analysis of four new cases and long-term evaluation of previously diagnosed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319705" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A kindred with Griscelli disease: spectrum of neurological involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996360" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Partial albinism with immunodeficiency (Griscelli syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11878584" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Griscelli syndrome: rare neonatal syndrome of recurrent hemophagocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207796" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835631" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403584" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Griscelli syndrome type 2: a rare and lethal disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897212" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11571516" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Griscelli syndrome: report of the first peripheral blood stem cell transplant and the role of mutations in the RAB27A gene as an indication for BMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2365795" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bone marrow transplantation (BMT) for the syndrome of pigmentary dilution and lymphohistiocytosis (Griscelli's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19403888" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20062095" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hematopoietic SCT in children with Griscelli syndrome: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195838" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10528861" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Schimke immuno-osseous dysplasia: case report and review of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653321" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2066860" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Schimke immuno-osseous dysplasia: a newly recognized multisystem disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8267014" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Schimke immuno-osseous dysplasia: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26499378" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lack of IL7Rαexpression in T cells is a hallmark of T-cell immunodeficiency in Schimke immuno-osseous dysplasia (SIOD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11799392" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796992" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Molecular assessment of thymic capacities in patients with Schimke immuno-osseous dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17089404" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Schimke immunoosseous dysplasia: suggestions of genetic diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16419127" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Schimke immuno-osseous dysplasia: a cell autonomous disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113849" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful bone marrow transplantation in a patient with Schimke immuno-osseous dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23950031" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bone marrow transplantation in Schimke immuno-osseous dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189087" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antibody deficiency, growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy: a novel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901296" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The cognitive and behavioural phenotype of Roifman syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21977988" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is Roifman syndrome an X-linked ciliopathy with humoral immunodeficiency? Evidence from 2 new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26522830" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863561" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Combined immunodeficiency, facial dysmorphism, optic nerve atrophy, skeletal anomalies and developmental delay: a new syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29180244" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dual loss of p110δPI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354791" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3189331" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cytogenetic findings in a prospective series of patients with DiGeorge anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8696341" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A common region of 10p deleted in DiGeorge and velocardiofacial syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10633131" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13/14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10935639" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : GATA3 haplo-insufficiency causes human HDR syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573133" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Preliminary phenotypic map of chromosome 4p16 based on 4p deletions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063753" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904122" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Parental origin of chromosome 4p deletion in Wolf-Hirschhorn syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18932224" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Update on the clinical features and natural history of Wolf-Hirschhorn (4p-) syndrome: experience with 87 patients and recommendations for routine health supervision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18932124" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9672528" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antibody deficiency in Wolf-Hirschhorn syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483677" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10103318" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
